Posted by Michael Wonder on 21 Jun 2023
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer
21 June 2023 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) in combination with lenvatinib mesylate (Lenvima) for the treatment of adults with advanced or recurrent endometrial cancer.
The combination of pembrolizumab and lenvatinib mesylate is recommended for the treatment of adults with advanced or recurrent endometrial cancer whose cancer has progressed on or after platinum-based chemotherapy and who cannot have curative surgery or radiotherapy.
